Rebecca Cook
Faculty Member
Last active: 4/15/2019

  1. HER4 D-box sequences regulate mitotic progression and degradation of the nuclear HER4 cleavage product s80HER4. Strunk KE, Husted C, Miraglia LC, Sandahl M, Rearick WA, Hunter DM, Earp HS, Muraoka-Cook RS (2007) Cancer Res 67(14): 6582-90
    › Primary publication · 17638867 (PubMed) · PMC2917069 (PubMed Central)
  2. The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. Muraoka-Cook RS, Sandahl M, Husted C, Hunter D, Miraglia L, Feng SM, Elenius K, Earp HS (2006) Mol Biol Cell 17(9): 4118-29
    › Primary publication · 16837552 (PubMed) · PMC1556387 (PubMed Central)
  3. Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1. Muraoka-Cook RS, Caskey LS, Sandahl MA, Hunter DM, Husted C, Strunk KE, Sartor CI, Rearick WA, McCall W, Sgagias MK, Cowan KH, Earp HS (2006) Mol Cell Biol 26(17): 6412-24
    › Primary publication · 16914727 (PubMed) · PMC1592831 (PubMed Central)
  4. Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM, Zent R, Arteaga CL (2006) Oncogene 25(24): 3408-23
    › Primary publication · 16186809 (PubMed)
  5. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, Arteaga CL, Neilson EG, Hayward SW, Moses HL (2005) Oncogene 24(32): 5053-68
    › Primary publication · 15856015 (PubMed) · PMC3074577 (PubMed Central)
  6. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Muraoka-Cook RS, Dumont N, Arteaga CL (2005) Clin Cancer Res 11(2 Pt 2): 937s-43s
    › Primary publication · 15701890 (PubMed)
  7. Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Muraoka-Cook RS, Kurokawa H, Koh Y, Forbes JT, Roebuck LR, Barcellos-Hoff MH, Moody SE, Chodosh LA, Arteaga CL (2004) Cancer Res 64(24): 9002-11
    › Primary publication · 15604265 (PubMed)
  8. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE, Moses HL, Arteaga CL (2003) Mol Cell Biol 23(23): 8691-703
    › Primary publication · 14612410 (PubMed) · PMC262670 (PubMed Central)
  9. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C, Chen J (2002) Oncogene 21(46): 7011-26
    › Primary publication · 12370823 (PubMed)
  10. ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Muraoka RS, Lenferink AE, Law B, Hamilton E, Brantley DM, Roebuck LR, Arteaga CL (2002) Mol Cell Biol 22(7): 2204-19
    › Primary publication · 11884607 (PubMed) · PMC133673 (PubMed Central)